MedTrace Logo

MindVybe tVNS/APS for Wellbeing in Breast Cancer Survivors

NCT07782866 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2026-08-24

No results posted yet for this study

Summary

This study tests whether a gentle, non-invasive device called mindvybe can help improve feelings of wellbeing in people who have had breast cancer. Mindvybe delivers mild electrical stimulation near the vagus nerve (on the ears and neck) and to specific points on the earlobes.

About 60 adults (ages 18-75) who finished breast cancer treatment within the past five years and still have ongoing wellbeing problems (such as low mood, stress, fatigue, or sleep issues) will take part. Participants will receive five 50-minute mindvybe sessions over one week. Researchers will measure changes in wellbeing, distress, fatigue, sleep, and heart-rate patterns before, during, and for up to 12 weeks after the sessions.

The study is open-label (everyone receives the same treatment) and is considered low-risk.

Conditions

Interventions

DEVICE

Transcutaneous vagus nerve and acupuncture point stimulation

Non-invasive transcutaneous stimulation delivered to the skin near the auricular and cervical branches of the vagus nerve and to acupuncture points on both earlobes using ultra-low electrical current. Participants receive five 50-minute sessions over a 7-day period.

Sponsors & Collaborators

  • The Healing Consciousness Foundation

    lead OTHER

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-14
Primary Completion
2026-07-24
Completion
2026-07-24

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07782866 on ClinicalTrials.gov